Scinai Immunotherapeutics Ltd. (NASDAQ:SCNI) Sees Large Decrease in Short Interest

Scinai Immunotherapeutics Ltd. (NASDAQ:SCNI) was the target of a significant drop in short interest during the month of December. As of December 31st, there was short interest totalling 1,200 shares, a drop of 71.4% from the December 15th total of 4,200 shares. Based on an average daily volume of 11,400 shares, the short-interest ratio is presently 0.1 days.

Scinai Immunotherapeutics Stock Performance

Shares of SCNI traded up $0.02 during mid-day trading on Tuesday, hitting $3.44. The stock had a trading volume of 3,304 shares, compared to its average volume of 10,950. Scinai Immunotherapeutics has a fifty-two week low of $2.23 and a fifty-two week high of $8.92. The company has a quick ratio of 1.16, a current ratio of 1.16 and a debt-to-equity ratio of 0.06. The company has a market cap of $2.93 million, a PE ratio of -0.01 and a beta of 2.34. The company’s fifty day simple moving average is $3.34 and its two-hundred day simple moving average is $3.61.

About Scinai Immunotherapeutics

Scinai Immunotherapeutics Ltd., a development stage biopharmaceutical company, focuses on developing, manufacturing, and commercializing products for the prevention and treatment of infectious and autoimmune diseases in Israel. It has licensing and collaboration agreement with Max Planck Society and University Medical Center Göttingen for the development and commercialization of COVID-19 nanosized antibody (NanoAb); and development and commercialization of NanoAbs for various other disease indications.